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Detection and treatment of pheochromocytomas
and paragangliomas:
current standing of MIBG scintigraphy
and future role of PET imaging
B. HAVEKES 1, 2, E. W. LAI 1, E. P. M. CORSSMIT 2, J. A. ROMIJN 2, H. J. L. M. TIMMERS 3, K. PACAK 1
Pheochromocytomas are rare tumors arising from chro-
maffin cells of adrenal medullary or extra-adrenal para-
ganglionic tissue. These tumors are characterized by
synthesis, storage, metabolism and secretion of cate-
cholamines. Similar to the sympathetic nervous system,
pheochromocytomas express cellular norepinephrine
transporters (NET) through which catecholamines can
enter pheochromocytoma cells to be stored in vesicles.
Metaiodobenzylguanidine (MIBG) resemblance to nor-
epinephrine and its good affinity and uptake by NET
resulted in its use in pheochromocytoma diagnosis from
1981. Both [123I]MIBG and [131I]MIBG (lower sensitivity)
scintigraphy are used for localization of these tumors.
Recent discoveries of different hereditary syndromes
associated with pheochromocytomas led to the identi-
fication of several and new distinct genotype-pheno-
type associations. Importantly, with this distinction of
clinical phenotypes, MIBG was found to have a different
performance in subsets of pheochromocytoma patients.
Reduced sensitivity of MIBG scintigraphy in some famil-
ial paraganglioma syndromes, malignant disease and
extra-adrenal paragangliomas has been found.
Therefore, newer compounds, especially for positron
emission tomography (PET), such as [11C]hydrox-
yephedrine ([11C]HED), [18F]fluoro-2-deoxy-D-glucose
([18F]FDG), [18F]fluoro-dihydroxyphenylalanine ([18F]
FDOPA) and [18F]fluorodopamine ([18F]FDA) have
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emerged and were found to be superior to MIBG in the
localization of certain types of pheochromocytoma and
paragangliomas. Finally, using [131I]MIBG represents an
important treatment option in patients with malignant
pheochromocytoma, but the development of newer
treatment modalities is expected. In this review, we pro-
vide the reader with an overview of the current stand-
ing of [123I]- and [131I]MIBG in diagnosis and treatment of
pheochromocytoma amongst the newer PET imaging
agents.
KEY WORDS: Pheochromocytomas - Paragangliomas -
Radionuclide imaging - Tomography, emission computed.
In 2004 the World Health Organization classifica-tion of endocrine tumors defined a pheochromo-
cytoma as an intra-adrenal paraganglioma, whereas
closely related tumors of extra-adrenal sympathetic
or parasympathetic paraganglia are classified as extra-
adrenal paragangliomas.1 In general, approximately
80% of the pheochromocytomas arise from the adren-
al medulla.2 Sympathetic paragangliomas are most
frequently found in the abdomen (extra-adrenal),
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pelvis and less often in the thorax. These sympathet-
ic paragangliomas almost all produce and most of
them secrete catecholamines or their metabolites. On
the other hand, head and neck paragangliomas, which
were formerly referred to as glomus tumors, are
derived from parasympathetic tissue and rarely pro-
duce significant amounts of catecholamines. The for-
mer estimate that, in general, approximately 10% of
paragangliomas and pheochromocytomas are malig-
nant is no longer valid. The prevalence of malignant
dedifferentiation depends directly on the underlying
genetic mutation.
Metaiodobenzylguanidine (MIBG) is a guanethi-
dine analogue resembling norepinephrine and is,
therefore, concentrated by sympatho-adrenergic tis-
sues, especially the chromaffin tissue of the adrenal
medulla. The uptake of MIBG in the cells is both dri-
ven by passive diffusion and by active uptake.3 MIBG
is an aralkylguanidine that can be labeled with iodine
isotopes at the benzoic ring. MIBG is taken up by
sympatho-medullary tissues via norepinephrine trans-
porters (NET) and deposited in storage granules,
which is facilitated by vesicular monoamine trans-
porters (VMAT). MIBG does not bind to postsynaptic
adrenergic receptors and, therefore, can be given
safely in higher doses. Iodine-131-MIBG has a long
half life of approximately 8.2 days, whereas [123I]MIBG
has a half life of only 13.2 h. In addition, γ camera effi-
ciency of the 159-keV [123I] isotope is approximately
4 times that of its 364-keV [131I] counterpart and
because of the absence of β-emission combined with
a shorter half-life, radiation dosimetry is more favor-
able.4 To prevent thyroid accumulation it is neces-
sary to block the thyroid gland with potassium iodide.
After 24 h and again at either 48 or 72 h after injection
of the MIBG the patient will be scanned. MIBG is
normally accumulated in myocardium (hence its use
in cardiac imaging), liver, spleen, lungs, cerebellum,
large intestine and urinary bladder.
In recent years, improvements in diagnosis, genetics,
localization, and treatment of pheochromocytomas
have changed dramatically the approaches to these
tumors. The prevalence of underlying genetic mutations
in apparently sporadic pheochromocytomas was found
to be much higher than was previously estimated.5
Hereditary pheochromocytomas occur in multiple
endocrine neoplasia type 2, von Hippel-Lindau syn-
drome (VHL), and neurofibromatosis type 1. The famil-
ial paraganglioma syndromes associated with muta-
tions in the succinate dehydrogenase genes (SDHB, C
or D) were more recently discovered as hereditary
causes for pheochromocytoma.6, 7 Several distinct geno-
type-phenotype associations among SDHB and SDHD
mutation carriers have since then been identified.8-10 For
example, patients with a mutation in the SDHB gene
have a risk for the development of malignant disease
up to 70%, whereas SDHD has been associated with
malignant disease in an estimated 2.5-5% of cases.11, 12
Importantly, the identification of these distinct para-
ganglioma syndromes prompted a reevaluation of the
value of both biochemical tests and radiological imag-
ing in these syndromes separately.
MIBG has been used in pheochromocytoma diag-
nosis since 1981. However, newer compounds for
positron emission tomography (PET) such as [18F]flu-
orodopamine ([18F]FDA) and [18F]fluoro-dihydroxy-
phenylalanine ([18F]FDOPA) have been developed in
recent years for the diagnosis of pheochromocytomas.
This article addresses and reviews three important
aspects of MIBG: a) its use as an imaging compound;
b) its performance in pheochromocytomas and para-
gangliomas in comparison to PET compounds; c) its
use as a carrier compound for 131I to treat malignant
pheochromocytoma and paraganglioma.
Metaiodobenzylguanidine as an imaging
compound in pheochromocytoma and
paraganglioma
The radiopharmaceutical agent [131I]MIBG, which
was first developed for adrenal scintigraphy and test-
ed on dogs and rhesus monkeys before its use, was
reported in a study of 8 pheochromocytoma patients
by Wieland et al. and Sisson et al.13-15 MIBG was
retained for days in tissues where adrenergic vesicles
were numerous such as pheochromocytomas, thus
offering a means of localization for these tumors.
Iodine-131-MIBG scintigraphy was found to have a
sensitivity of 77-90% and a specificity of 95-100%.16-18
Because [123I]MIBG generates a higher dose of γ-rays
with a higher specificity, the imaging quality greatly
improved. In 1986, Shulkin et al. illustrated the supe-
riority of [123I]MIBG over [131I]MIBG in a patient with
a primary extra-adrenal pheochromocytoma.19
Subsequent studies confirmed that the use of the [123I]
isotope resulted in a better performance with a sen-
sitivity of 83-100% and a specificity of 95-100%.18, 20-24
Additional advantages of the [123I] isotope are the pos-
sibility to use single photon emission computed
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tomography (SPECT) imaging and the fact that a low-
er half life facilitates the use of higher dosages.
Importantly, the normal adrenal medullary may
show physiological uptake of both [131I]- and
[123I]MIBG.25, 26 In [131I]MIBG imaging normal adrenals
are visualized in up to 28% of cases (24 and 48 h).27, 28
Cases studied using [123I]MIBG have been reported to
reveal MIBG uptake to a greater extent in normal
adrenal medullary tissue than [131I]MIBG.4 Diffuse
adrenal medullary hyperplasia could be responsible
for false positive MIBG uptake.29 However, exempli-
fying the importance of underlying genetic mutations,
this condition appears to be associated with the MEN
type 2 syndromes with a well-established risk for
pheochromocytoma development. The difficulty is to
decide whether or not uptake of [123I]MIBG reflects
physiological uptake, adrenal hyperplasia or a
pheochromocytoma. In an attempt to improve the
accuracy of [123I]MIBG in patients with adrenal or
extra-adrenal pheochromocytoma, Cecchin et al.
assessed the usefulness of a scoring system based on
the different uptakes of the radiopharmaceutical
between different organs. A scoring system (1: uptake
absent or less than liver; 2: uptake equal to the liver;
3: uptake moderately more intense than the liver; 4:
uptake intense) was introduced and scintigraphies
were classified as positive if there was extra-adrenal
focal uptake, adrenal enlargement combined with
non-homogeneous uptake or adrenal uptake which
was higher than the uptake in the liver (scores 3 and
4).22 The results were correlated with postoperative
histological outcomes and a sensitivity of 91.5% and
a specificity of 100% were reported in the localization
of adrenal and extra-adrenal pheochromocytomas.
Positive and negative predictive values were report-
ed to be 100% and 83%, respectively. According to the
authors, using the liver uptake as a reference value
resulted in a correct discrimination of physiological
adrenal uptake in 18 out of 20 cases.
Suboptimal sensitivity of MIBG might be associated
with the relatively low affinity of MIBG to the NET, the
lack of storage granules or the loss of NET or VMAT by
tumor cell dedifferentiation.30 Furthermore, several
types of medication could interfere with MIBG uptake
in patients (Table I) resulting in false-negative results.31
Several studies have reported the diagnostic value of
MIBG scans to be dependent on size and location of
the tumor. Reduced sensitivity of MIBG scans in famil-
ial paraganglioma syndromes, malignant disease and
extra-adrenal paragangliomas has been described.21, 32-
35 Van der Harst et al. found MIBG scanning to be less
sensitive for familial paraganglioma, malignant dis-
ease and extra-adrenal localization.32 Van der Horst-
Schrivers et al. reported sensitivity to be 98% for extra-
adrenal tumors and 79% in malignant cases.33 The
results in a recent study by Bhatia et al.34 revealed
tumor detection in only 58% of the extra-adrenal
tumors, whereas 85% of the adrenal pheochromocy-
tomas could be detected. Tumor size correlated with
the uptake for adrenal but not for extra-adrenal tumors,
which could be a reflection of uptake in small adren-
al tumors being obscured by the influence of physio-
logic adrenal accumulation. Therefore, in general,
diagnostic accuracy of MIBG was lower in extra-
adrenal and malignant paragangliomas.
With growing knowledge about the genetic back-
ground of various pheochromocytoma and paragan-
glioma syndromes, the evaluation of MIBG scintigra-
phies focused more on the familial pheochromocy-
toma and paraganglioma syndromes. Kaji et al. report-
ed that 3 out of 7 patients with an adrenal pheochro-
mocytoma associated with VHL had negative results
utilizing [123/131I]MIBG.36 Their results suggested low-
er sensitivity of MIBG in VHL and they suspected this
to be due to the low expression of NET in VHL-relat-
ed pheochromocytoma cells. The recent discovery of
the SDH genes as a hereditary cause for pheochro-
mocytomas and extra-adrenal paragangliomas sup-
ported the idea of the existence of different subgroups
in familial pheochromocytoma and further addressed
the need for proper imaging to detect tumors located
outside the adrenals. Several earlier studies, like the
TABLE I.—Interfering pharmaceuticals that may affect imaging
with MIBG.
Interfering Necessary length
pharmaceuticals of cessation Mechanismbefore MIBG
Labetalol 72 hours Inhibition uptake
Reserpine 21 days Storage depletion
Calcium channel blockers 72 hours Inhibition uptake
Tricyclic antidepressants 21 days Storage depletion
Phenylephrine 48 hours Storage depletion
Pseudoephedrine 48 hours Storage depletion
Phenylpropanolamine 48 hours Storage depletion
Ephedrine 48 hours Storage depletion
Atypical antidepressants 21 days Inhibition uptake
Others (e.g. SSRIs)
MIBG: metaiodobenzylguanidine; SSRI: selective serotonin reuptake inhi-
bitor. [Adapted from: Solanki et al.31].
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paper from van der Harst et al.32 had not specifically
addressed MIBG accuracy in SDHD and SDHB muta-
tion carriers separately. It is possible that a consider-
able number of patients in their large sporadic group
were carriers of mutations in the SDH genes, because
SDHB-related PGL often present as apparently spo-
radic tumors, as was described by Timmers et al.10
Only very few studies have investigated the specific
value of MIBG scans in SDHD mutation carriers. Based
on a study by Van Houtum et al.37 and unpublished
data from the Netherlands, we estimate the sensitivi-
ty in SDHD patients to be around 80% for detecting
pheochromocytomas and extra-adrenal (abdominal
and thoracic) paragangliomas combined with an
increase in sensitivity to 92% for pheochromocytomas
alone. SDHB mutation carriers often display a much
more aggressive course of the disease and are prone
to developing extra-adrenal malignant disease.
Timmers et al. reported a sensitivity of only 65% for
[123I]MIBG in the evaluation of metastases-positive
lesions in SDHB-associated pheochromocytoma and
paraganglioma.38 In conclusion, the different geno-
type-phenotype associations are most likely also
reflected by differences in the performance of imag-
ing with [123/131I]MIBG (Table II).
Some reports have questioned routine use of MIBG
imaging in the diagnostic work-up for pheochromo-
cytoma, suggesting that it does not alter the treatment
plan in patients with suspected pheochromocytoma in
the absence of hereditary disease or a history of
pheochromocytoma.40 In a retrospective study,
Miskulin et al. concluded that in non-familial cases
with a clear biochemical diagnosis and a unilateral
adrenal mass on computed tomography (CT) or mag-
netic resonance imaging (MRI), no additional MIBG
imaging is necessary.44 Although this is a valid rec-
ommendation, it needs to be stressed that this is true
mainly with regard to epinephrine secreting tumors
which are located in the adrenals, whereas the nor-
epinephrine secreting tumors, which are frequently
found in familial paraganglioma syndromes, often pre-
sent recurrent, extra-adrenal, and bilateral disease.
Furthermore, especially in older patients, benign adren-
al adenomas are often found and can be wrongly con-
sidered to be a pheochromocytoma. Another concern
with MIBG scintigraphy is that, since MIBG is rela-
tively non-polar, the nonspecific binding is fairly high
directly after injection and optimal imaging results are
not achieved until 24 h or several days after injection,
which is inconvenient for patient care, as is the need
to prevent thyroid accumulation with potassium iodide.
Metaiodobenzylguanidine and its performance
in pheochromocytomas and paragangliomas
in comparison to PET compounds
Because of the above mentioned potential shortfalls
of both [123I]- and [131I]MIBG in the imaging of espe-
cially extra-adrenal and malignant paragangliomas,
TABLE II.—Estimated functional imaging performance in separate genotypes.
specific PET non-specific PET[123/131I]MIBG (18F]FDA, ([18F]FDG) Selected references[18F]FDOPA)
VHL + ++ Insufficient data Kaji et al.36,
Hoegerle et al.39
MEN + + Insufficient data Greenblatt et al.40,
Pacak et al.41
SDHB + ++ *++/++++* Timmers et al.10
Timmers et al.38
SDHC Insufficient data Insufficient data Insufficient data —
SDHD + Insufficient data Insufficient data Van Houtum et al.37
Non-familial** **+** **++** **++** Hoegerle et al.39,
Shulkin et al.42, 43,
Mackenzie et al.35
*Metastatic SDHB-associated disease; **several studies performed before discovery of succinate dehydrogenase gene mutations, SDH associated disease may
present as sporadic. MIBG: metaiodobenzylguanidine; PET: positron emission tomography; FDA: fluorodopamine; FDOPA: fluoro-dihydroxyphenylalanine;
FDG: fluoro-2-deoxy-D-glucose; VHL: von Hippel Lindau; MEN: multiple endocrine neoplasia; SDH: succinate dehydrogenase type B, C or D; FDG: fluoro-
2-deoxy-D-glucose.
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newer means of imaging have been extensively stud-
ied. Somatostatin receptors have been demonstrated
on paragangliomas (Figure 1) and somatostatin recep-
tor imaging in pheochromocytomas/paragangliomas
revealed some favorable results.46-48 Investigation of
[111In]pentetreotide in pheochromocytoma identified
most tumors, but appeared to be inferior to the use of
MIBG.49-51 In 2001, van der Harst et al. reviewed their
experience of preoperative [123I]MIBG and a labeled
somatostatin analog in the diagnostic work-up in
pheochromocytoma patients and concluded that
somatostatin receptor imaging might be considered as
a supplement for MIBG in suspected metastatic dis-
ease.32 However, both the expression of NET and the
somatostatin receptor may be lost in a dedifferentiat-
ed tumor, resulting in false negative imaging in
metastatic disease.32, 51
PET was developed in the late seventies and has
become a more common imaging modality in the
imaging of pheochromocytoma in recent years.52, 53
Compounds used in PET imaging generate positrons
that can be detected with high resolution images and
their relatively short half-lives compared with other
radiopharmaceuticals increases the maximal dose that
can be administered safely. PET scanning offers bet-
ter resolution than SPECT, because signal to noise
ratios are increased due to the relatively intense
radioactivity and coincidence detection. Furthermore,
recent developments enabled to combine conven-
tional imaging methods like CT with PET further
improving its diagnostic use.54 Studies focused on dis-
covery of carriers that could be labeled with positron
emitting compounds and still maintain the specificity
of MIBG with its selective uptake via the NET. Carbon-
11-hydroxyephedrine ([11C]HED) is another analogue
of norepinephrine and was the first positron-emitting
probe of the sympathoadrenal system that was used
in humans.55, 56 In 1992, Shulkin et al. reported promis-
Figure 1.Chromaffin cell with its specific (left) and less-specific targets (right) for functional imaging. 1: aminoacid uptake; 2: norepi-
nephrine transporter (hNET); 3: somatostatin receptor; 4: GLUT 1 glucose transporter; TH: tyrosine hydroxylase; L-AADC: L-aromatic-
aminoacid decarboxylase; DBH: dopamine-β-hydroxylase; PNMT: phenylethanolamine-N-methyltransferase. [Adapted from Ilias et al.45].
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ing results of [11C]HED in the localization of pheochro-
mocytoma.57 Carbon-11-HED is more polar than
MIBG, has even greater similarities with norepineph-
rine and has a very short half-life of only 20 min.
Visualization of the [11C] radiotracer was done by the
use of PET techniques. The authors reported [11C]HED
to accumulate in 9 out of 10 patients, both in benign
and malignant pheochromocytoma, only 5 min after
injection. However, the synthesis of the [11C]HED com-
pound was very complex and required onsite pro-
duction for each separate patient because of the very
short half-life of the compound. Furthermore, these
agents may be subject to interference with the same
agents known to interfere with MIBG, because they
both use the catecholamine uptake pathway. In con-
clusion, although [11C]HED had introduced the new
field of PET imaging as a promising approach in
pheochromocytoma diagnosis, the need for other
positron-emitting compounds with a slightly longer
half-life, like [18F] (half-life 110 min), was evident.
Fluorine-18-fluorodopamine
Dopamine is a much better substrate for the NET
than norepinephrine itself.30 Therefore, it was hypoth-
esized that a labeled analog of dopamine could be use-
ful for scintigraphy of pheochromocytoma. Fluorine-
18-FDA is a sympatho-neuronal imaging agent that
was developed at the National Institutes of Health
and is a substrate for the transporters in catecholamine
synthesizing cells, both those at the membrane and the
intracellular vesicular transporters.30 Fluorine-18 has
the advantage that it can usually be incorporated into
a molecule with only small effects on the ability of the
carrying compound to bind to receptors, or be taken
up by their transporters. The result is that the ratio tis-
sue-blood is more than 1 000 which results in a good
visualization of cells.58 Clinical studies have revealed
that [18F]FDA is indeed a good imaging agent for
pheochromocytoma.36, 59-61 In 2003, Ilias et al. showed
the superiority of [18F]FDA imaging over [131I]MIBG
scintigraphy, especially in malignant tumors.62 For
PET scanning, patients were studied fasting and caf-
feine, tobacco and alcohol were avoided for at least
12 h to prevent interference with the imaging, because
caffeine is an adrenergic stimulant and the others may
influence gastrointestinal motility. However, [18F]FDA
is difficult to produce and has limited availability. Like
MIBG uptake, uptake of [18F]FDA in normal adrenal
glands may lead to false-positive results, because of
physiologic uptake. Recently, Timmers et al. have
reported the usefulness of standardized uptake values
for distinguishing adrenal glands with pheochromo-
cytoma from those without.63 The diagnosis of
pheochromocytoma was estimated to be highly unlike-
ly if the SUV was <7.3, whereas a SUV >10.1 con-
firmed the presence of a pheochromocytoma.
Importantly, the possibility of genotype-specific
properties in performance of [18F]FDA imaging must
be reemphasized. Its superiority was proven in the
detection of pheochromocytoma in a selected cohort
of only VHL mutation carriers,36 however, specific
data on [18F]FDA performance in patient cohorts with
other genotypes are scarce and will have to be further
investigated. 
Fluorine-18-dihydroxyphenylalanine
Newer modes of imaging have been developed
based on the capabilities of uptake and subsequent
decarboxylation of amino acids (like DOPA) in neu-
roendocrine tumors. DOPA can be decarboxylated to
dopamine by L-amino acid decarboxylase (L-AADC),
which is shown in Figure 1. This L-AADC enzyme is
strongly expressed in neuroendocrine cells and it is
evident that cells producing catecholamines may have
up regulated amino acid transporters because of the
increased demand for precursors. Although, for
instance, [11C]methionine and [11C]tyrosine are taken
up via the same transporter system, they do not accu-
mulate as well in neuroendocrine cells as [18F]FDOPA,64
suggesting it is only possible for those tracers with a
high affinity for L-AADC to remain in the cells. It is sug-
gested that the fact that [18F]FDOPA is converted to
[18F]FDA which is subsequently stored in intracellular
vesicles may well be the explanation for the ability to
localize with these compounds. In 2002, Hoegerle et
al. described [18F]FDOPA PET imaging to outperform
[123I]MIBG scintigraphy in the detection of pheochro-
mocytoma.39 As was described above, positron emit-
ters tend to have higher spatial resolution and the
selective uptake results in imaging within minutes-
hours instead of the, at least, 24 h needed in both
[123I]- and [131I]MIBG imaging. Furthermore, several
studies have noted the lack of uptake in normal adren-
al glands,65, 66 whereas [123I]MIBG reveals some degree
of accumulation in normal adrenal glands stressing the
importance for evaluation of asymmetric uptake.
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Therefore, [18F]FDOPA could be a sensitive and spe-
cific tool in the diagnostic strategy of pheochromo-
cytoma and paraganglioma.64 Timmers et al. recently
reported that carbidopa enhances the sensitivity of
[18F]FDOPA for adrenal pheochromocytomas and
extra-adrenal abdominal paragangliomas by increas-
ing the tumor-to-background ratio of tracer uptake.
However, the sensitivity of [18F]FDOPA for metastatic
paragangliomas was limited.67
Fluorine-18-fluoro-2-deoxy-D-glucose
Fluorine-18-fluoro-2-deoxy-D-glucose ([18F]FDG) is
the most frequently used PET imaging agent world-
wide. Fluorine-18-FDG PET imaging uses the princi-
ple of imaging glucose uptake via GLUT-1 receptors
in tumors with excess uptake of glucose (e.g. meta-
bolically active tumor cells). Fluorine-18-FDG is tak-
en into the cells and subsequently trapped by hex-
okinase-phosphorylation, thus making it resistant to
further glycolysis.68 Fluorine-18-FDG uptake is fre-
quently increased in tumors that are metabolically
active and have abundant mitochondria.69 However,
because cancer cells often display high rates of aero-
bic glycolysis instead of the oxidative phosphorylation
pathway via the tri-carboxylic-acid cycle (TCA), also
termed the Warburg effect, [18F]FDG uptake is not
directly proportional to mitochondrial activity alone.70
However, since [18F]FDG tumor imaging depends pri-
marily on the level of glucose uptake by the tumor
cells as a reflection of the level of metabolic activity,
it offers little diagnostic specificity. Nonetheless,
[18F]FDG localization studies may differentiate between
benign and (metabolically more active) malignant
tumors. Shulkin et al. have reported most pheochro-
mocytomas, both benign and metastasized, to show
uptake of [18F]FDG.42, 43 Fluorine-18-FDG uptake
appeared to be unrelated to the secretory status of
the tumor. Mann et al. reported a study in suspected
pheochromocytoma patients where both [11C]HED
and [18F]FDG were able to localize more lesions in a
more timely fashion than [131I]MIBG.53 In a recent
large study, Timmers et al. showed that [18F]FDG is a
superior means of visualization in patients with SDHB
associated malignant pheochromocytomas.38
Therefore, we believe [18F]FDG imaging in pheochro-
mocytomas could be reserved for those patients with
SDHB metastatic disease or those that had been neg-
ative on other functional imaging studies.
Metaiodobenzylguanidine and its role as
carrier for 131I to treat malignant
pheochromocytoma and paraganglioma
Patients with metastatic paragangliomas have a 5-
year-overall survival of approximately 50%.71
Treatment options in surgically incurable situations
are limited. Several studies have reported partial or
complete response to have occurred with cyclophos-
phamide, vincristine and dacarbazine (CVD)
chemotherapy.72 Although chemotherapy may length-
en survival and can be useful for palliative care, the
fact that it is associated with significant side effects
necessitates an individualized approach. The expres-
sion of NET on pheochromocytoma cells does not
only provide a method for imaging of these tumors,
but could also offer a means for selectively targeting
these tumors for treatment.
Iodine-131-MIBG as an experimental treatment for
metastasized pheochromocytoma was first reported in
1984.20, 73 Several studies have since published about
the use of [131I]MIBG as a radiotoxic drug to treat
pheochromocytomas.74-78 In 1991, Shapiro et al. report-
ed results of a 10 year experience and reported par-
tial tumor response in 8/28 patients with only mild
radiotoxicity.74 A review performed by Loh et al.
showed tumor response in up to 30% of 116 report-
ed patients.79 Extended analyses concluded that, in
general, a (mostly partial) tumor response was to be
expected in 24-45% of the patients, but disease pro-
gression after 2 years was common.80, 81 In line with
this finding are the recent results of a retrospective
study in 19 patients with a median cumulative dose of
22.2 GBq that revealed tumor response in 47% patient
of patients, a biochemical response rate of 67%, where-
as no less than 89% of patients mentioned a sympto-
matic response.77 Side effects on bone marrow range
from mild thrombopenia and leucopenia to overt
bone marrow failure, especially in those patients with
massive skeletal localizations and higher doses. In
addition, although the thyroid had been blocked with
potassium iodide, the development of hypothyroidism
was possible. Furthermore, higher doses have been
reported to result in nausea. However, most studies
have been small and had a retrospective design with
comparisons made even more difficult because of
different doses and treatment intervals.
Usually, patients are treated with multiple medium
doses of [131I]MIBG of around 7.4 GBq. Rose et al.
suggested in 2003 that higher individual doses might
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result in increased survival, based upon their study in
which 12 patients were treated with a median single
treatment dose of 37 GBq leading to 3 patients with
a complete and 7 patients with a partial response.82
Patients had peripheral blood stem cell leukapheresis
prior to therapy, unless patients had proven bone
marrow metastases. The follow-up study by Fitzgerald
et al. calculated a 5-year survival of 75% from time of
treatment, but stressed the need for newer treatments.83
Importantly, the level of hematological side effects
was much higher; especially grade 3 thrombocy-
topenia was very frequent (79%). Perhaps repeated
intermediate-dosage [131I]MIBG treatment, as was advo-
cated by Lam et al. could provide a useful addition in
the therapeutic arsenal without the excess of hema-
tological toxicity.84
Because malignant pheochromocytomas are rare, no
randomized trials have been performed directly com-
paring the response of CVD chemotherapy with those
of [131I]MIBG treatment. In a recent review, Scholz et
al. concluded that [131I]MIBG therapy and CVD
chemotherapy were comparable with regard to both
response rate and side effects.72 As appears to be the
case in imaging, treatment results may be expected to
vary considerably between patient cohorts with dif-
ferent underlying genetic mutations, which is subject
to further prospective and retrospective studies.
Somatostatin receptors have been demonstrated on
paragangliomas/pheochromocytomas, and this con-
cept has been used for diagnostic imaging purposes
(Figure 1). However, results concerning targeted
radionuclide therapy using radiolabeled somatostatin
analogues in these tumors are scarcer.85, 86 Successful
use of [177Lu]DOTA0-Tyr3-octreotate in paragangliomas
has been reported.85 Recently, Forrer et al. reported
that treatment with 90Y- and 117Lu-labeled somato-
statin compounds could have long lasting responses
with minimal toxicity and could therefore be consid-
ered in somatostatin receptor positive surgically incur-
able paragangliomas.87 However, most radiolabeled
somatostatin analogues target the somatostatin recep-
tor type 2 which may have a low or variable expres-
sion, resulting in less efficacy of treatment.88 Malignant
pheochromocytomas may have more expression of
type 3 and 5 somatostatin receptors than type 2, so,
at least in theory, labeled somatostatin analogues with
broader receptor specificity might be more effective
in selected cases.88
Current treatment options will be further refined
in the future. So called ‘no-carrier added high specif-
ic activity’ [131I]MIBG has been reported to improve
efficacy of the delivered radiotherapy by increased
tumor uptake.89 Normally, the uptake of [131I]MIBG
may be competitively inhibited by the presence of
[127I]MIBG, which is formed during the synthesis of
[131I]MIBG. Using a ‘non-carrier’ method of synthesis
reduces the amount of ‘cold’ MIBG with subsequent-
ly increased [131I]MIBG uptake and effect of therapy.
The development of alternative substrates to MIBG for
the NET and storage system will play a role as well.
Among these analogues promising results have been
suggested for 3-[211At]astatobenzylguanidine ([211At]
MABG), which has α-emitting characteristics and a
prolonged retention in the targeted tissue.90, 91
Local perfusion of affected organs via intra-arteri-
al catheters could facilitate the delivery of the radio-
pharmaceutical compound directly to the tumor in
individual patients with metastasized disease located
in distinct organs. Brogsitter et al. reported patients
with carcinoids that had a fourfold increase in local
delivery of [131I]MIBG using local perfusion.92
Another promising approach is the attempt to
increase the expression of key components in the
uptake and storage of norepinephrine (and its ana-
logues) to improve the delivery of [131I]MIBG and
related radiopharmaceuticals. Recent preliminary
developments include increasing tumor accumula-
tion of MIBG by altering NET expression93, 94 or
approaches integrating norepinephrine transporter
gene transfer with radionuclide targeting.95, 96 Some in
vitro studies suggest MIBG uptake will increase after
chemotherapy.97 Some reports have mentioned dox-
orubicin and cisplatin increasing the effectiveness of
[131I]MIBG as a treatment modality in neuroblastoma.93,
97, 98
Conclusions, suggested algorithm
and future prospects
In conclusion, the diagnostic and therapeutic strate-
gies in pheochromocytoma have changed dramati-
cally over the last few years. Underlying gene mutations
have been identified in a much larger proportion of
pheochromocytoma patients than was previously
expected. Increased performance of MRI and CT imag-
ing, MIBG, and the emergence of newer means for
functional imaging have tremendously increased the
diagnostic accuracy in pheochromocytoma diagnosis.
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Because of its better accuracy and the fact that they are
much more patient friendly, we expect [18F]FDOPA
and/or [18F]FDA to (at least partly) replace MIBG in
diagnostic imaging for pheochromocytoma and para-
ganglioma in the future. In metastatic, highly meta-
bolically active SDHB-associated paragangliomas
[18F]FDG will certainly be of value, albeit with limited
specificity. Future studies will have to take into account
the different genotype-phenotype associations with
varying imaging performances and provide head-to-
head comparisons of imaging methods in these specific
subsets of patients. Therapy with [131I]MIBG will remain
an essential part of the treatment of malignant
pheochromocytomas and paragangliomas, but devel-
opments in improving uptake and efficiency can be
expected. Currently, clinical trials are being conduct-
ed at Duke University with [131I]MIBG preparations
synthesized without the unwanted carrier molecules
(cold contaminants). Clinical trials comparing high-
dose [131I]MIBG vs smaller repeated doses vs combi-
nations with chemotherapeutic regimens are needed.
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